Rice, MD Anderson receive $1.5 million to further brain cancer research

fresh funding

Rice and MD Anderson scientists are researching new methods for treating brain cancer by overcoming the blood-brain barrier. Photo via Getty Images.

Rice University chemist Han Xiao, who also serves as director of the university’s Synthesis X Center, and cancer biologist Dihua Yu of The University of Texas MD Anderson Cancer Center have received a three-year, $1.5 million grant from the Robert J. Kleberg Jr. and Helen C. Kleberg Foundation.

The funding will allow them to continue their research on treating brain metastasis by overcoming the blood-brain barrier, or the BBB, according to a news release.

Brain metastasis is the leading form of brain cancer, with survival rates below 20 percent within a year of diagnosis, according to the National Library of Medicine. It commonly originates from breast, lung and melanoma cancers.

The BBB typically acts as a protective barrier for the brain. However, it prevents most drugs from being able to directly reach the brain. According to Rice, only 2 percent of FDA-approved small molecule drugs can penetrate the BBB, limiting treatment options.

Xiao and Yu’s approach to dealing with the BBB includes a light-induced brain delivery (LIBD) platform. The advanced system employs nanoparticles that are embedded with a near-infrared dye for the transport of therapeutic agents across the BBB. The research will evaluate the LIBD’s ability to improve the delivery of small-molecule drugs and biological therapies. Some therapies have shown potential for reducing cancer growth in laboratory studies, but they have struggled due to limited BBB penetration in animal models.

“Our LIBD platform represents a novel strategy for delivering drugs to the brain with precision and efficiency,” Xiao said in a news release. “This technology could not only improve outcomes for brain metastasis patients but also pave the way for treating other neurological diseases.”

The Kleberg Foundation looks for groundbreaking medical research proposals from leading institutions that focus on “innovative basic and applied biological research that advances scientific knowledge and human health” according to the foundation.

“This research is a testament to the power of collaboration and innovation,” Xiao said in a news release. “Together, we’re pushing the boundaries of what’s possible in treating brain metastasis and beyond.”

Rice launched the Synthesis X Center, or Synth X, last spring. It was born out of what started about eight years ago as informal meetings between Xiao's research group and others from the Baylor College of Medicine’s Dan L Duncan Comprehensive Cancer Center. It aims to turn fundamental research into clinical applications through collaboration.

“This collaboration builds on the strengths of both research teams,” Xiao said in the release. “By combining SynthX Center's expertise in chemistry with Dr. Yu's expertise in cancer biology and brain metastases, we aim to create a transformative solution.”

From Your Site Articles
Innovators in immunotherapy, precision drug discovery, monoclonal antibodies, and diagnostic and therapeutic technologies have joined TMC's Accelerator for Cancer Therapeutics. Photo courtesy TMC.

TMC names 2025 cohort of cancer treatment innovators

ready to grow

Texas Medical Center Innovation has named more than 50 health care innovators to the fifth cohort of its Accelerator for Cancer Therapeutics (ACT).

The group specializes in immunotherapy, precision drug discovery, monoclonal antibodies, and diagnostic and therapeutic technologies, according to a statement from TMC.

During the nine-month ACT program, participants will enjoy access to a network of mentors, grant-writing support, chemistry resources, and the entrepreneur-in-residence program. The program is designed to equip participants with the ability to secure investments, develop partnerships, and advance the commercialization of cancer therapeutics in Texas.

“With over 35 million new cancer cases predicted by 2050, the urgency to develop safer, more effective, and personalized treatments cannot be overstated,” Tom Luby, chief innovation officer at Texas Medical Center, said in a news release.

Members of the new cohort are:

  • Alexandre Reuben, Kunal Rai, Dr. Cassian Yee, Dr. Wantong Yao, Dr. Haoqiang Ying, Xiling Shen, and Zhao Chen, all of the University of Texas MD Anderson Cancer Center
  • Dr. Andre Catic and Dr. Martin M. Matzuk, both of the Baylor College of Medicine
  • Cynthia Hu and Zhiqiang An, both of UTHealth Houston
  • Christopher Powala, Aaron Sato, and Mark de Souza, all of ARespo Biopharma
  • Daniel Romo, Dr. Susan Bates, and Ken Hull, all of Baylor University
  • Eugene Sa & Minseok Kim, both of CTCELLS
  • Gomika Udugamasooriya and Nathaniel Dawkins, both of the University of Houston
  • Dr. Hector Alila of Remunity Therapeutics
  • Iosif Gershteyn and Victor Goldmacher, both of ImmuVia
  • João Seixas, Pedro Cal, and Gonçalo Bernardes, all of TargTex
  • Ken Hsu and Yelena Wetherill, both of the University of Texas at Austin
  • Luis Martin and Dr. Alberto Ocaña, both of C-Therapeutics
  • Dr. Lynda Chin, Dr. Keith Flaherty, Dr. Padmanee Sharma, James Allison, and Ronan O’Hagan, all of Project Crest/Apricity Health
  • Michael Coleman and Shaker Reddy, both of Metaclipse Therapeutics
  • Robert Skiff and Norman Packard, both of 3582.ai
  • Rolf Brekken, Uttam Tambar, Ping Mu, Su Deng, Melanie Rodriguez, and Alexander Busse, all of UT Southwestern Medical Center
  • Ryan Swoboda and Maria Teresa Sabrina Bertilaccio, both of NAVAN Technologies
  • Shu-Hsia Chen and Ping-Ying Pan, both of Houston Methodist
  • Thomas Kim, Philipp Mews, and Eyal Gottlieb, all of ReEngage Therapeutics
The ACT launched in 2021 and has had 77 researchers and companies participate. The group has collectively secured more than $202 million in funding from the NIH, CPRIT and venture capital, according to TMC.

Cellenkos Therapeutics has completed promising Phase 1b testing of its Treg cell therapy, CK0804, in the fight against myelofibrosis. Photo via Getty Images

Houston biotech company tests hard-to-fight cancer therapeutics

fighting cancer

A Houston-based, female-founded biotech company has developed a treatment that could prove to be an effective therapy for a rare blood cancer.

Cellenkos Therapeutics has completed promising Phase 1b testing of its Treg cell therapy, CK0804, in the fight against myelofibrosis. According to a news release from the Cellenkos team, the use of its cord-blood-derived therapeutics could signal a paradigm shift for the treatment of this hard-to-fight cancer.

Cellenkos was founded by MD Anderson Cancer Center physician and professor Simrit Parmar. Her research at the hospital displayed the ability of a unique subset of T cells’ capability to home in on a patient’s bone marrow, restoring immune balance, and potentially halting disease progression.

Myelofibrosis has long been treated primarily with JAK (Janus Kinase) inhibitors, medications that help to block inflammatory enzymes. They work by suppressing the immune response to the blood cancer, but don’t slow the progression of the malady. And they’re not effective for every patient.

“There is a significant need for new therapeutic options for patients living with myelofibrosis who have suboptimal responses to approved JAK inhibitors,” Parmar says. “We are greatly encouraged by the safety profile and early signs of efficacy observed in this patient cohort and look forward to continuing our evaluation of the clinical potential of CK0804 in our planned expansion cohort.”

The expansion cohort is currently enrolling patients with myelofibrosis. What exactly are sufferers dealing with? Myelofibrosis is a chronic disease that causes bone marrow to form scar tissue. This makes it difficult for the body to produce normal blood cells, leaving patients with fatigue, spleen enlargement and night sweats.

Myelofibrosis is rare, with just 16,000 to 18,500 people affected in the United States. But for patients who don’t respond well to JAKs, the prognosis could mean a shorter span than the six-year median survival rate outlined for the disease by Cleveland Clinic.

Helping myelofibrosis patients to thrive isn’t the only goal for Cellenkos right now.

The company seeks to aid people with rare conditions, particularly inflammatory and autoimmune disorders, with the use of CK0804, but also other candidates including one known as CK0801. The latter drug has shown promising efficacy in aplastic anemia, including transfusion independence in treated patients.

The company closed its $15 million series A round led by BVCF Management, based in Shanghai, in 2021. Read more here.

Several Houston institutions scored funding from the Cancer Prevention and Research Institute of Texas. Photo via Getty Images

German biotech co. to relocate to Houston thanks to $4.75M CPRIT grant

money moves

Armed with a $4.75 million grant from the Cancer Prevention and Research Institute of Texas, a German biotech company will relocate to Houston to work on developing a cancer medicine that fights solid tumors.

Eisbach Bio is conducting a clinical trial of its EIS-12656 therapy at Houston’s MD Anderson Cancer Center. In September, the company announced its first patient had undergone EIS-12656 treatment. EIS-12656 works by suppressing cancer-related genome reorganization generated by DNA.

The funding from the cancer institute will support the second phase of the EIS-12656 trial, focusing on homologous recombination deficiency (HRD) tumors.

“HRD occurs when a cell loses its ability to repair double-strand DNA breaks, leading to genomic alterations and instability that can contribute to cancerous tumor growth,” says the institute.

HRD is a biomarker found in most advanced stages of ovarian cancer, according to Medical News Today. DNA constantly undergoes damage and repairs. One of the repair routes is the

homologous recombination repair (HRR) system.

Genetic mutations, specifically those in the BCRA1 and BCRA1 genes, cause an estimated 10 percent of cases of ovarian cancer, says Medical News Today.

The Cancer Prevention and Research Institute of Texas (CPRIT) says the Eisbach Bio funding will bolster the company’s “transformative approach to HRD tumor therapy, positioning Texas as a hub for innovative cancer treatments while expanding clinical options for HRD patients.”

The cancer institute also handed out grants to recruit several researchers to Houston:

  • $2 million to recruit Norihiro Goto from the Massachusetts Institute of Technology to MD Anderson.
  • $2 million to recruit Xufeng Chen from New York University to MD Anderson.
  • $2 million to recruit Xiangdong Lv from MD Anderson to the University of Texas Health Science Center at Houston.

In addition, the institute awarded:

  • $9,513,569 to Houston-based Marker Therapeutics for a first-phase study to develop T cell-based immunotherapy for treatment of metastatic pancreatic cancer.
  • $2,499,990 to Lewis Foxhall of MD Anderson for a colorectal cancer screening program.
  • $1,499,997 to Abigail Zamorano of the University of Texas Health Science Center at Houston for a cervical cancer screening program.
  • $1,497,342 to Jennifer Minnix of MD Anderson for a lung cancer screening program in Northeast Texas.
  • $449,929 to Roger Zoorob of the Baylor College of Medicine for early prevention of lung cancer.

On November 20, the Cancer Prevention and Research Institute granted funding of $89 million to an array of people and organizations involved in cancer prevention and research.

The Cancer Bioengineering Collaborative announced the projects that were selected for its first round of seed grants. Photo via Rice.edu

2 Houston health innovation leaders award grants to cancer-fighting researchers

dream team

Five cancer-fighting research projects were named inaugural recipients of a new grant program founded by two Houston institutions.

Last summer, Rice University and The University of Texas MD Anderson Cancer Center announced they were teaming up to form the new Cancer Bioengineering Collaborative. The shared initiative, created to form innovative technologies and bioengineering approaches to improve cancer research, diagnosis and treatment, recently launched with an event at the TMC3 Collaborative Building in Helix Park.

At the gathering, the Cancer Bioengineering Collaborative announced the projects that were selected for its first round of seed grants.

  • “Enhancing CAR-T immunotherapy via precision CRISPR/Cas-based epigenome engineering of high value therapeutic gene targets,” led by Isaac Hilton, associate professor of biosciences and bioengineering at Rice and a Cancer Research and Prevention Institute of Texas (CPRIT) scholar; and Michael Green, associate professor of lymphoma/myeloma at MD Anderson.
  • “Nanocluster and KRAS inhibitor-based combination therapy for pancreatic ductal adenocarcinoma,” led by Linlin Zhang, assistant research professor of bioengineering at Rice; and Haoqiang Ying, associate professor of molecular and cellular oncology at MD Anderson.
  • “Engineering tumor-infiltrating fusobacteriumas a microbial cancer therapy,” led by Jeffrey Tabor, professor of bioengineering at Rice; and Christopher Johnston, associate professor of genomic medicine and director of microbial genomics within the Platform for Innovative Microbiome and Translational Research at MD Anderson.
  • “Preclinical study of nanoscale TRAIL liposomes as a neoadjuvant therapy for colorectal cancer liver metastasis,” led by Michael King, the E.D. Butcher Professor of Bioengineering at Rice, CPRIT scholar and special adviser to the provost on life science collaborations with the Texas Medical Center; and Xiling Shen, professor of gastrointestinal medical oncology at MD Anderson.
  • “Deciphering molecular mechanisms of cellular plasticity in MDS progression,” led by Ankit Patel, assistant professor of electrical and computer engineering at Rice and of neuroscience at Baylor College of Medicine; and Pavan Bachireddy, assistant professor of hematopoietic biology and malignancy and lymphoma/myeloma at MD Anderson.

The event was a who’s who of Houston-based cancer specialists. Speakers included our city’s favorite Nobel laureate, Jim Allison, director of the James P. Allison Institute, as well as MD Anderson’s vice president of research, Eyal Gottlieb. Attendees were welcomed by the leaders of the initiative, Rice’s Gang Bao and MD Anderson’s Jeffrey Molldrem.

“This collaborative initiative builds on the strong foundation of our existing relationship, combining Rice’s expertise in bioengineering, artificial intelligence and nanotechnology with MD Anderson’s unmatched insights in cancer care and research,” Rice’s president Reginald DesRoches says at the event. “This is a momentous occasion to advance cancer research and treatment with the innovative fusion of engineering and medicine.”

The collaboration is part of Rice’s 10-year strategic plan for leadership in health innovation, called “Momentous: Personalized Scale for Global Impact.” Its goals include a commitment to responsible use of cutting-edge AI.

“As both institutions continue to make breakthroughs every day, we hope this collaborative will enable us to tackle the complex challenges of cancer care and treatment more effectively, ultimately improving the lives of patients here in Houston and beyond," Carin Hagberg, senior vice president and chief academic officer at MD Anderson, adds. "Whether our researchers are working on the South Campus or within the hedges of Rice, this collaborative will strengthen each other’s efforts and push the boundaries of what is possible in cancer.”

MD Anderson's lab led by Nobel laureate James Allison has secured a $5 million donation. Photo courtesy of MD Anderson Cancer Center

Cancer-fighting Houston lab led by Nobel laureate receives $5M grant at annual event

supporting research

The James P. Allison Institute at The University of Texas MD Anderson Cancer Center scored a $5 million gift at its second annual symposium.

On behalf of Mayor John Whitmire, Oct. 10, 2024 was named “James P. Allison Institute Day,” and it was also the day that the TMC3 Collaborative Building in the Texas Medical Center’s Helix Park greeted 900 attendees for the scientific symposium, entitled “Immunotherapy in Space and Time: The Tumor Microenvironment.”

Allison, who won the Nobel Prize in 2018, leads his namesake institute that was founded in 2022 to advance translational and clinical within cancer to create new, synergetic therapies. In addition to his role as director of the institute, he is regental professor and chair of Immunology at MD Anderson.

At the symposium, Jack and Judi Johnson presented a $5 million gift to the Allison Institute on behalf of the David and Eula Wintermann Foundation, a private organization dedicated to funding the advancement of medical education and research. A longtime supporter of MD Anderson, the foundation’s donation will go towards recruitment and technology for the institute, as well help fund clinical trials.

The money will help support several researchers, who will be known as Wintermann Scholars. The chosen great minds run the gamut from early career scientists to world-renowned experts in fields including immunotherapy, genetics, cancer biology, data science, bioinformatics, spatial profiling or the microbiome.

“It was clear to us that the work happening within the Allison Institute has the potential to transform the lives of so many patients,” said Johnson, president of the Wintermann Foundation. “Our hope is that, with our support, we can help close the distance from the lab to the clinic so the incredible advancements underway can sooner help more cancer patients and their families.”

But the attendees on Oct. 10 learned far more than that. They were treated to a conversation between Allison and Carolyn Bertozzi, also a Nobel laureate, moderated by Alice Park, a senior health correspondent at Time. Park also took part in a fireside chat with Allison institute leaders, joined by MD Anderson President Peter WT Pisters and Chief Scientific Officer Giulio Draetta. Additional sessions also included presentations from big names like Mark Dawson, Elizabeth Jaffee, and Philip Greenberg.

“Spatial biology is a rapidly expanding field that offers tremendous new insights into immunobiology that were not possible just a few short years ago. Understanding how immune cells interact with their neighbors and with tumor cells in space and time will enable us to bring forward new strategies to improve immunotherapy outcomes,” said Allison. “We are proud to host this annual symposium to advance the field, and we are extremely grateful for the support of the Wintermann Foundation to make new breakthroughs possible.”

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston VC funding surged in Q1 2025 to highest level in years, report says

by the numbers

First-quarter funding for Houston-area startups just hit its highest level since 2022, according to the latest PitchBook-NVCA Venture Monitor. But fundraising in subsequent quarters might not be as robust thanks to ongoing economic turmoil, the report warns.

In the first quarter of 2025, Houston-area startups raised $544.2 million in venture capital from investors, PitchBook-NVCA data shows. That compares with $263.5 million in Q1 2024 and $344.5 million in Q1 2023. For the first quarter of 2022, local startups nabbed $745.5 million in venture capital.

The Houston-area total for first-quarter VC funding this year fell well short of the sum for the Austin area (more than $3.3 billion) and Dallas-Fort Worth ($696.8 million), according to PitchBook-NVCA data.

While first-quarter 2025 funding for Houston-area startups got a boost, the number of VC deals declined versus the first quarters of 2024, 2023 and 2022. The PitchBook-NVCA Monitor reported 37 local VC deals in this year’s first quarter, compared with 45 during the same period in 2024, 53 in 2023, and 57 in 2022.

The PitchBook-NVCA report indicates fundraising figures for the Houston area, the Austin area, Dallas-Fort Worth and other markets might shrink in upcoming quarters.

“Should the latest iteration of tariffs stand, we expect significant pressure on fundraising and dealmaking in the near term as investors sit on the sidelines and wait for signs of market stabilization,” the report says.

Due to new trade tariffs and policy shifts, the chances of an upcoming rebound in the VC market have likely faded, says Nizar Tarhuni, executive vice president of research and market intelligence at PitchBook.

“These impacts amplify economic uncertainty and could further disrupt the private markets by complicating investment decisions, supply chains, exit windows, and portfolio strategies,” Tarhuni says. “While this may eventually lead to new domestic investment and create opportunities, the overall environment is facing volatility, hesitation, and structural change.”

Expert: Texas is building a cybersecurity wall — but it needs more bricklayers

Guest Column

Texas has always been a state that thinks in terms of scale. Big energy, big ambitions and now, big action in cybersecurity.

With the creation of the Texas Cyber Command under the Department of Information Resources, the state is recognizing what many of us in the industry have long understood: cybersecurity is not just an IT issue, it's a matter of public safety and economic resilience. Protecting municipal systems, schools, and critical energy infrastructure from cyber threats is no longer optional. It is essential.

For these efforts to succeed, Texas must invest as much in people as it does in technology. Without a capable, well-trained workforce to carry out the mission, even the strongest cyber strategies will struggle to hold the line.

The scope of the threat

Cyberattacks are not theoretical. In the last year alone, several cities in Texas experienced major ransomware attacks. One incident in Fort Worth took down core city systems, affecting everything from email access to permitting operations. The ripple effects were significant.

The energy sector is also under constant pressure. As a cornerstone of both the Texas and national economy, the it is a high-value target. Hackers are probing systems that manage oil, gas, and renewable energy infrastructure, looking for weaknesses that could be exploited to steal data or disrupt operations.

Texas has responded by centralizing its cyber incident response capabilities. The Texas Cyber Command is a smart step forward. It brings coordination and focus to an increasingly complex landscape. But its effectiveness will depend entirely on the professionals tasked with doing the work. And that’s where the challenge lies.

The workforce gap

Across the U.S., there are an estimated 400,000 unfilled cybersecurity positions. In Texas, more than 40,000 roles remain vacant, according to CyberSeek. These are not just numbers in a report. They represent a growing vulnerability with gaps in frontline defenses against real and persistent threats.

We cannot afford to rely solely on traditional pathways to fill this gap. Four-year degree programs are important, but they are not designed to scale fast enough or flexibly enough to meet today’s needs. Instead, we need to broaden our view of what a cybersecurity talent pipeline looks like and who it includes.

There needs to be an expanded focus on practical, skills-based training that takes high-aptitude individuals, including those from non-traditional backgrounds, and prepares them for success in cybersecurity careers through rigorous hands-on training that reflects the demands of real-world cyber roles. With the right structure and support, people from all walks of life are already proving they can become capable defenders of our digital infrastructure.

The same entrepreneurial spirit that drives innovation in other sectors can be applied to cybersecurity workforce development. We don’t have to wait years to grow the next generation of defenders. We can do it now, with the right focus and investment.

Texas has taken a critical first step by creating the Cyber Command, but if we want to build lasting resilience, we need to address the workforce bottleneck head-on. Cybersecurity needs more than tech…it needs talent.

---

Dean Gefen is theCEO, NukuDo, a San Antonio-based cybersecurity workforce development and staffing company.

Rice Business Plan Competition doles out $2M to 2025 student teams

big winners

Celebrating its 25th year, the Rice Alliance for Technology and Entrepreneurship hosted the celebrated Rice Business Plan Competition this month, doling out more than $2 million in investment and cash prizes to the top-performing teams.

“For 25 years, the Rice Business Plan Competition has helped shape how Rice Business shows up in the world by creating a platform where student-entrepreneurs can tackle some of the most complex challenges of our time in energy, in health care, in technology and beyond,” Peter Rodriguez, dean of Rice Business, the presenting sponsor of the event, said in a news release. “If we’re serious about changing the world — and I believe we are — then it’s our responsibility to open doors for students everywhere to imagine bold solutions and build what comes next.”

Over the course of the three-day event, the 42 startups competing this year from colleges or universities around the world presented their plans before more than 300 angel, venture capital, and corporate investors. The teams were selected from the event’s largest applicant pool to date and represented 34 universities across four countries, according to Rice. Winners were announced at the company showcase and awards ceremony April 12 in downtown Houston.

Seven finalists were selected, though each team left the competition with some form of funding, according to Rice. The University of Michigan's Intero Biosystems was the star of the show, bringing home both the top-place finish and the largest total investment. Rice's own Pattern Materials also had a strong showing, placing fourth in the pitch competition and also earning the fourth-highest investment total.

Here are the teams that won big in 2025. See a full list of winners and prizes here.

Intero Biosystems, University of Michigan - $902,000

The team finished in first place for its GastroScreen, the first stem cell-driven human “mini gut” that is ideal for organ function testing before testing on humans, and also claimed the largest total investments among the competition.

  • $150,000 Goose Capital Investment Grand Prize
  • $250,000 Goose Capital Investment Prize
  • $200,000 The OWL Investment Prize
  • $100,000 Houston Angel Network Investment Prize
  • $100,000 nCourage Investment Network’s Courageous Women Entrepreneur Investment Prize
  • $100,000 Investment Prize from Nancy Chang
  • $1,000 Mercury Elevator Pitch Competition - Overall Winner
  • $1,000 Anbarci Family Company Showcase Prize
  • TMC Innovation Healthcare Accelerator Bootcamp Invitation Prize

MabLab, Harvard University – $301,500

The team placed second for its rapid test capable of detecting multiple adulterants in laced drugs and spiked drinks.

  • $100,000 Investment Prize, sponsored by David Anderson, Anderson Family Fund, Jon Finger and Finger Interests
  • $100,000 The Indus Entrepreneurs (TiE) Texas Angels Investment Prize
  • $25,000 nCourage Investment Network’s Courageous Women Entrepreneur Investment Prize
  • $50,000 Valhalla Investment Network Investment Prize
  • $25,000 The Eagles Investor Investment Prize
  • $500 Mercury Elevator Pitch Competition - Life Science*
  • $1,000 Anbarci Family Company Showcase Prize

re.solution, RWTH Aachen University — $76,500

The team placed third for its water-based technology that recycles polyesters without generating salt waste, making textile recycling viable.

  • $50,000 Investment Prize, sponsored by David Anderson, Anderson Family Fund, Jon Finger and Finger Interests
  • $25,000 Pearland EDC Spirit of Entrepreneurship Cash Prize
  • $500 Mercury Elevator Pitch Competition - Energy/Cleantech
  • $1,000 Anbarci Family Company Showcase Prize

Pattern Materials, Rice University – $134,500

The Houston-based team placed fourth for its laser-induced graphene technology that can be rapidly performed, enabling low-cost, scalable production of the material.

  • $5,000 prize, sponsored by Norton Rose Fulbright
  • $50,000 Valhalla Investment Network Investment Prize
  • $25,000 Pearland EDC Spirit of Entrepreneurship Cash Prize
  • $25,000 New Climate Ventures Sustainable Investment Prize
  • $25,000 Amentum and WRX Companies Rising Stars Space Technology and Commercial Aerospace Cash Prize
  • $500 Mercury Elevator Pitch Competition - Hard Tech
  • $1,000 Anbarci Family Company Showcase Prize
  • $3,000 Venture Builder Innovation Prizes

Xatoms, Western University and University of Toronto — $30,000

The team placed fifth for its AI- and quantum-driven platform for discovering solar-activated semiconductor materials.

  • $5,000 prize, sponsored by EY
  • $25,000 nCourage Investment Network’s Courageous Women Entrepreneur Investment Prize

Mito Robotics, Carnegie Mellon University— $5,000

The team placed sixth for its automated manual cell culture with AI-powered robotic scientists for life science research

  • $5,000 prize, sponsored by Chevron Technology Ventures

FarmSmart.ai, LSU – $106,000

The team placed seventh for its AI—driven assistant that synthesizes vast agricultural research into actionable, tailored intelligence, but earned the fifth-most investments among the group.

  • $5,000 prize, sponsored by Shell Ventures
  • $100,000 The OWL Investment Prize
  • $1,000 Anbarci Family Company Showcase Prize
  • Edward H. Molter Memorial Prizes for Wildcard Round - 1st place - Advance to Finals


Other significant awards

GreenLIB Materials, University of Ottawa – $152,000

  • $150,000 Goose Capital Investment Prize
  • $2,000 Venture Builder Innovation Prizes

Microvitality, Tufts University – $26,500

  • $25,000 Southwest National Pediatric Device Consortium Pediatric Device Cash Prize
  • $1,500 Edward H. Molter Memorial Prizes for Wildcard Round - 3rd place overall in WC

Nanoborne, University of Texas at Austin - $25,000

  • $25,000 NOV Golden Ticket to Supernova Accelerator and Cash Prize

Last year, the Rice Business Plan Competition facilitated over $1.5 million in investment and cash prizes. MesaQuantum from Harvard University landed the highest total investment last year, although it was not named a finalist. Protein Pints from Michigan State University won the pitch competition.

According to Rice, 910 startups have raised more than $6.9 billion in capital through the competition over the last 25 years.

View All Listings